ӳ��ý

A Curated Resource for Phosphosite-specific Signature Analysis.

Krug K, Mertins P, Zhang B, et al. A Curated Resource for Phosphosite-specific Signature Analysis. Mol Cell Proteomics. 2019;18(3):576-593. doi:10.1074/mcp.TIR118.000943

Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.

Stover EH, Baco MB, Cohen O, et al. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. Mol Cancer Res. 2019;17(11):2281-2293. doi:10.1158/1541-7786.MCR-18-1243

Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer.

Shee K, Yang W, Hinds JW, et al. Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. J Exp Med. 2018;215(3):895-910. doi:10.1084/jem.20171818

RWEN: response-weighted elastic net for prediction of chemosensitivity of cancer cell lines.

Basu A, Mitra R, Liu H, Schreiber SL, Clemons PA. RWEN: response-weighted elastic net for prediction of chemosensitivity of cancer cell lines. Bioinformatics. 2018;34(19):3332-3339. doi:10.1093/bioinformatics/bty199

Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor.

Bowers A, West N, Taunton J, Schreiber SL, Bradner JE, Williams RM. Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor. J Am Chem Soc. 2008;130(33):11219-22. doi:10.1021/ja8033763

Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer.

Gallenne T, Ross KN, Visser NL, et al. Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer. Oncotarget. 2017;8(13):20572-20587. doi:10.18632/oncotarget.16244

Synthetic Lethal Vulnerabilities in -Mutant Cancers.

Aguirre AJ, Hahn WC. Synthetic Lethal Vulnerabilities in -Mutant Cancers. Cold Spring Harb Perspect Med. 2018;8(8). doi:10.1101/cshperspect.a031518

IGF2 mRNA binding protein-2 is a tumor promoter that drives cancer proliferation through its client mRNAs IGF2 and HMGA1.

Dai N, Ji F, Wright J, Minichiello L, Sadreyev R, Avruch J. IGF2 mRNA binding protein-2 is a tumor promoter that drives cancer proliferation through its client mRNAs IGF2 and HMGA1. Elife. 2017;6. doi:10.7554/eLife.27155

High-throughput identification of noncoding functional SNPs via type IIS enzyme restriction.

Li G, Martínez-Bonet M, Wu D, et al. High-throughput identification of noncoding functional SNPs via type IIS enzyme restriction. Nat Genet. 2018;50(8):1180-1188. doi:10.1038/s41588-018-0159-z

Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups.

Archer TC, Ehrenberger T, Mundt F, et al. Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2018;34(3):396-410.e8. doi:10.1016/j.ccell.2018.08.004